Allogeneic hematopoietic cell transplantation (HCT) is commonly associated with hepatic
complications. Patients with myelofibrosis (MF) often develop liver dysfunction in the early …

Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only curative
treatment for myelofibrosis (MF). Relapse occurs in 10–30% and remains a major factor for …

Factors predicting allogeneic hematopoietic cell transplantation (HCT) outcomes in
myelofibrosis in the early post-HCT period have not been defined thus far. We attempt to …

Allogeneic hematopoieteic stem cell transplantation (HSCT) is the only curative treatment for
myelofibrosis (MF), but it is still associated with significant risks and complications. One of …

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for
myelofibrosis. Most post-transplantation events occur during the first two years and hence …

Therapeutic management of patients with primary or secondary myelofibrosis (MF) who
experience relapse or graft failure following allogeneic haematopoietic cell transplantation …

We aimed to evaluate the determinants of survival in myelofibrosis patients undergoing
allogeneic hematopoietic cell transplantation (allo-HCT) and to describe factors predicting …

To develop a prognostic model for patients undergoing allogeneic hematopoietic cell
transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients …

Summary Allogeneic Haematopoietic Stem Cell Transplant (allo‐HSCT) remains the only
curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the …

Background Myelofibrosis is a myeloproliferative stem cell disorder curable exclusively by
allogeneic hematopoietic stem cell transplantation and is associated with substantial …